12 Month Price Forecast For DNA
Distance to DNA Price Forecasts
DNA Price Momentum
๐ค Considering Ginkgo Bioworks (DNA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 6:32 AM UTC
DNA Analyst Ratings & Price Targets
Based on our analysis of 11 Wall Street analysts, DNA has a bearish consensus with a median price target of $8.00 (ranging from $6.00 to $16.00). Currently trading at $13.52, the median forecast implies a -40.8% downside. This outlook is supported by 1 Buy, 1 Hold, and 4 Sell ratings.
Conversely, the most conservative target is provided by Gaurav Goparaju at Berenberg, suggesting a 55.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DNA Analyst Consensus
DNA Price Target Range
Latest DNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DNA.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Sep 20, 2024 | TD Cowen | Brendan Smith | Buy | Maintains | $10.00 |
Aug 23, 2024 | BTIG | Mark Massaro | Sell | Maintains | $7.00 |
Jul 9, 2024 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $0.30 |
Jun 26, 2024 | BTIG | Mark Massaro | Sell | Maintains | $0.20 |
May 15, 2024 | BTIG | Mark Massaro | Sell | Downgrade | $0.00 |
May 15, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $1.00 |
May 10, 2024 | William Blair | Matt Larew | Underperform | Downgrade | $0.00 |
Mar 1, 2024 | TD Cowen | Steven Mah | Outperform | Maintains | $3.00 |
Jan 23, 2024 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $1.10 |
Jan 22, 2024 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $1.10 |
Nov 15, 2023 | Raymond James | Rahul Sarugaser | Market Perform | Downgrade | $2.50 |
Nov 14, 2023 | Raymond James | Rahul Sarugaser | Market Perform | Downgrade | $2.50 |
Nov 9, 2023 | BTIG | Mark Massaro | Neutral | Downgrade | $0.00 |
Jun 5, 2023 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $1.25 |
Jun 2, 2023 | Goldman Sachs | Matthew Sykes | Sell | Downgrade | $1.25 |
May 11, 2023 | William Blair | Matt Larew | Market Perform | Downgrade | $0.00 |
Nov 29, 2022 | Berenberg | Gaurav Goparaju | Buy | Initiates | $6.00 |
Oct 4, 2022 | Morgan Stanley | Tejas Savant | Equal-Weight | Initiates | $5.00 |
Aug 16, 2022 | BTIG | Mark Massaro | Buy | Maintains | $6.00 |
Aug 16, 2022 | Raymond James | Rahul Sarugaser | Outperform | Maintains | $14.50 |
Stocks Similar to Ginkgo Bioworks Holdings, Inc.
The following stocks are similar to Ginkgo Bioworks based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ginkgo Bioworks Holdings, Inc. (DNA) Financial Data
Ginkgo Bioworks Holdings, Inc. has a market capitalization of $777.11M with a P/E ratio of -0.7x. The company generates $217.95M in trailing twelve-month revenue with a -298.8% profit margin.
Revenue growth is +60.6% quarter-over-quarter, while maintaining an operating margin of -58.7% and return on equity of -63.5%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Ginkgo Bioworks Holdings, Inc. (DNA) Company Overview
About Ginkgo Bioworks Holdings, Inc.
Develops cell programming platforms for biotechnology.
The company operates a platform that programs cells to produce various biological products, including therapeutics, food ingredients, and chemicals. It generates revenue by serving a diverse range of industries such as pharmaceuticals, agriculture, and consumer technology.
Founded in 2008 and headquartered in Boston, Ginkgo Bioworks is positioned at the intersection of biotechnology and synthetic biology, targeting applications that address global challenges in health, food, and environmental sustainability.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
1,218
CEO
Dr. Jason Kelly Ph.D.
Country
United States
IPO Year
2021
Website
www.ginkgobioworks.comGinkgo Bioworks Holdings, Inc. (DNA) Latest News & Analysis
Ginkgo Bioworks (NYSE: DNA) will host the 2025 Ferment Series, an evolution of its annual conference, aiming to advance its mission in cell programming and biosecurity in Boston's Seaport District.
The Ferment conference highlights Ginkgo Bioworks' commitment to innovation in biotechnology, potentially driving investor interest and confidence in its growth and market position.
Ginkgo Bioworks (DNA) saw increased trading volume recently, but recent earnings estimate revisions may hinder its short-term upward momentum.
Ginkgo Bioworks' significant trading volume indicates heightened interest, but negative earnings estimate revisions could signal potential declines, affecting investor sentiment and future stock performance.
Ginkgo Bioworks (DNA) has received a Zacks Rank #1 (Strong Buy) upgrade, indicating increasing optimism about its earnings prospects.
Ginkgo Bioworks' upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving stock price upward.
Ginkgo Bioworks will design an anaerobic lab automation system for the University of Wisconsin's GLBRC to enhance biofuel research, supporting multiple teams in biomass conversion.
Ginkgo Bioworks' new automation system enhances biofuel research efficiency, potentially leading to faster innovations and market readiness in sustainable energy, impacting future growth and profitability.
SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development
21 days agoSaponiQx has partnered with Probius and Ginkgo Bioworks, funded by DTRA, to enhance saponin-based adjuvant discovery and development for chemical and biological defense.
The collaboration enhances innovation in biotechnology, potentially leading to breakthroughs in drug development, impacting market competitiveness and long-term growth prospects for involved companies.
Ginkgo Bioworks (NYSE: DNA) partners with Universal Cells to enhance iPSC-derived cancer therapies using its cell engineering platform, focusing on solid tumor treatments.
The collaboration enhances Ginkgo Bioworks' position in biotech, potentially increasing its market value and attracting investor interest due to advancements in cancer therapies.
Frequently Asked Questions About DNA Stock
What is Ginkgo Bioworks Holdings, Inc.'s (DNA) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Ginkgo Bioworks Holdings, Inc. (DNA) has a median price target of $8.00. The highest price target is $16.00 and the lowest is $6.00.
Is DNA stock a good investment in 2025?
According to current analyst ratings, DNA has 1 Buy ratings, 1 Hold ratings, and 4 Sell ratings. The stock is currently trading at $13.52. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for DNA stock?
Wall Street analysts predict DNA stock could reach $8.00 in the next 12 months. This represents a -40.8% decrease from the current price of $13.52. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ginkgo Bioworks Holdings, Inc.'s business model?
The company operates a platform that programs cells to produce various biological products, including therapeutics, food ingredients, and chemicals. It generates revenue by serving a diverse range of industries such as pharmaceuticals, agriculture, and consumer technology.
What is the highest forecasted price for DNA Ginkgo Bioworks Holdings, Inc.?
The highest price target for DNA is $16.00 from at , which represents a 18.3% increase from the current price of $13.52.
What is the lowest forecasted price for DNA Ginkgo Bioworks Holdings, Inc.?
The lowest price target for DNA is $6.00 from Gaurav Goparaju at Berenberg, which represents a -55.6% decrease from the current price of $13.52.
What is the overall DNA consensus from analysts for Ginkgo Bioworks Holdings, Inc.?
The overall analyst consensus for DNA is bearish. Out of 11 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 4 as Sell, with a median price target of $8.00.
How accurate are DNA stock price projections?
Stock price projections, including those for Ginkgo Bioworks Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.